Temozolomide plus thalidomide in patients with brain metastases from melanoma

Temozolomide plus thalidomide is a promising oral combination regimen for the treatment of metastatic melanoma. The current Phase II study examined the efficacy and safety of this combination in chemotherapy‐naive patients with brain metastases.

[1]  S. Legha.  Treatment of brain metastases from melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Gore,et al.  Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Shannon,et al.  Determinants of outcome in melanoma patients with cerebral metastases. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Sepkowitz,et al.  Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Menell,et al.  Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Clough,et al.  Selection of Patients With Melanoma Brain Metastases for Aggressive Treatment , 2003, American journal of clinical oncology.

[7]  A. Roccaro,et al.  Thalidomide: a new anticancer drug? , 2003, Expert opinion on investigational drugs.

[8]  M. Ranson,et al.  Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[10]  R. Parker,et al.  A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Menell,et al.  Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Rustin,et al.  Effect of temozolomide on central nervous system relapse in patients with advanced melanoma , 2002, Melanoma research.

[13]  H. Gogas,et al.  Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Raizer,et al.  Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. , 2001, The Lancet. Oncology.

[15]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[16]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Messaris,et al.  Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? , 2000, Journal of neurosurgical sciences.

[18]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[19]  C. Scheibenbogen,et al.  Long‐term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin‐2 in poor risk melanoma patients , 1998, Melanoma research.

[20]  M. Roddie,et al.  Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.

[21]  P. Haslett,et al.  Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset , 1998, The Journal of experimental medicine.

[22]  R. MacKie,et al.  Cerebral metastases of cutaneous melanoma. , 1997, British Journal of Cancer.

[23]  S. Handt,et al.  Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. , 1996, Immunopharmacology.

[24]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.